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Abstract
Introduction: People with intellectual disabilities (ID) are earlier frail than people in the general population. Although this
may be explained by lifelong unfavourable social, psychological and clinical causes, underlying physiological pathways might be
considered too. Biological measures can help identify pathophysiological pathways. Therefore, we examined the association
between frailty and a range of serum markers on inﬂammation, anaemia, the metabolic system, micronutrients and renal
functioning.
Methods: Participants (n = 757) with borderline to severe ID (50+) were recruited from three Dutch ID care and support
services.
Results: Frailty was measured with a frailty index, a measure based on the accumulation of deﬁcits. Linear regression analyses
were performed to identify associations between frailty and biochemical measures independent of age, gender, level of ID and
the presence of Down syndrome. Frailty appears associated with inﬂammation (IL-6 and CRP), anaemia, metabolic markers
(glucose, cholesterol and albumin) and renal functioning (cystatin-C and creatinine).
Discussion: These results are in line with results observed in the general population. Future research needs to investigate the
causal relation between biochemical measures and frailty, with a special focus on inﬂammation and nutrition. Furthermore, the
possibility to screen for frailty using biochemical measures needs to be used.
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Introduction
Although people with Down syndrome and people with
severe intellectual disabilities (ID) have shorter life
expectancies than the general population, the average life ex-
pectancy of people with ID is increasing [1]. As a result,
frailty, a state in which older people are prone to negative
health outcomes including disability, hospitalisation,
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institutionalisation and premature death [2], can become a
major problem. In people with ID, early onset and high
levels of frailty were observed [3], but the underlying path-
ways leading to the early onset of frailty in this population
have not yet been investigated.
Frailty is a complex cascade that involves several physio-
logical alterations, eventually leading to loss of function and
failure to respond to stressor events [2]. The physiological
mechanisms underlying the onset and development of frailty
remain complicated and poorly understood. Even so, frailty
has been associated with dysregulation in several physiologic-
al systems including the inﬂammatory system, the endocrine
system, musculoskeletal functioning, metabolism and speciﬁc
diseases including cardiovascular diseases and renal failure
[2]. Biomarkers involved in these mechanisms have been
associated with the prevalence [4] and incidence of frailty
[5, 6, 7]. Although several biochemical measures show strong
associations with frailty, there is not yet one biomarker that
can adequately identify frailty [8]. Nevertheless, information
on biochemical measures can provide useful information on
underlying physiological processes leading to frailty. For
example, nutritional deﬁciencies could reﬂect insufﬁcient
(micro)nutrient intake, problems with the gastrointestinal
tract or an increased utilisation. Knowledge about the relation
between (micro)nutrient status and frailty could promote
interventions to limit (micro)nutrient deﬁciencies. In add-
ition, eventually biochemical measures can help to screen
and identify those at high risk to develop frailty (Figure 1).
Knowledge about dysregulation in physiological systems
and its association with frailty has not yet been investigated
in people with ID. Information from the general population
might not be applicable to the ID population, because the
development of frailty and its relation with biochemical pro-
cesses may be different in this population because of lifelong
unfavourable chronic conditions, environmental factors, life
style and genetic factors (Figure 1). Previously, Carmeli et al.
[9] found high inﬂammatory markers in healthy adults with
unspeciﬁed ID compared with those without ID, but it has
not yet been studied whether these high inﬂammatory
markers are associated with overall health status. Therefore,
in the present, explorative study, we aimed at assessing the as-
sociation between frailty (in terms of deﬁcit accumulation)
and physiological processes in older people with ID.
Materials and methods
Subjects and study design
This study was part of the ‘Healthy aging and intellectual dis-
abilities’ study (HA-ID) [10]. In this observational study, in-
formation was collected on the general health status of older
people with ID using formal care in the Netherlands. Three
Dutch care provider services for people with ID offering a
broad spectrum of care, ranging from ambulatory support to
residential care, collaborated in this study. Together they pro-
vided care to 2,322 clients with borderline to profound ID
aged 50 and over, who were all invited to participate.
Eventually, 1,050 clients participated in the HA-ID study,
forming a study population nearly representative for the
Dutch population of adults aged 50 and above with ID who
receive formal care. Those capable of understanding the
available information signed the consent form themselves.
Legal representatives were approached for those not able to
make this decision. Details about recruitment, design, inclu-
sion criteria and representativeness have been published else-
where [10]. The Medical Ethics Committee of the Erasmus
Medical Center Rotterdam (MEC-2008-234) and the ethics
committees of the participating care organisations approved
this study. Data collection included body measurements,
physical ﬁtness tests, questionnaires and laboratory tests in
Figure 1. Schematic representation of the pathway of frailty and the role of biochemical measures.
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addition to ﬁle records. Data on age, gender and residential
status were retrieved from the administrative systems.
Residential status was categorised as centralised setting,
community-based setting and living independently or with
relatives with ambulatory support. Level of ID was obtained
from the records of behavioural therapists and psychologists
and was classiﬁed as borderline (intelligence quotient (IQ)
70–80), mild (IQ 55–70), moderate (IQ 35–55), severe (IQ
25–35) or profound (IQ < 25).The presence of Down syn-
drome was retrieved from the medical ﬁles. Medical ﬁles
were used to determine the used medication. The following
ATC codes were used to classify drugs that could interfere
with the included biochemical values: A10 for glucose-
lowering drugs, B03A for haemoglobin-related drugs, C10
for lipid-lowering drugs, A12A for calcium supplements, and
A11CC and A11CB for vitamin D supplements.
Blood samples
Blood samples were drawn in Becton Dickinson collection
tubes by a trained medical assistant in the morning following
an 8 h overnight fast (November 2008–July 2010). The
samples were centrifuged, and serum was stored at −80°C
until the measurements. CRP, haemoglobin and all metabolic
markers were analysed at the laboratory of the Erasmus
Medical Center, which is a reference laboratory. Calcium was
determined on a Beckman Coulter DxC analyser. Vitamin-D3
(25-OH vitamin-D) measurements were performed using
an electrochemiluminescence immunoassay with polyclonal
antibodies on a Cobas-E module (Roche Diagnostics®, 128
Penzberg, Germany). Creatinine and cystatin-C were mea-
sured using the Cobas 8000 Modular Analyzer from Roche
Diagnostics AG (Rotkreuz, Switzerland). IL-6 was analysed
for this study speciﬁcally. The level of IL-6 was quantiﬁed
using a sensitive enzyme-linked immunosorbent assay (ELISA;
Human IL6 Elisa Ready-SET-Go! cat no. 88-7066). The lower
detection limit for IL-6 was 19.5 pg/ml.
Constructing the frailty index
Frailty was measured with a frailty index (FI), an operationalisa-
tion of frailty that focuses on the quantity, rather than on the
nature of health problems [11]. It captures physical, psycho-
logical and social health and has been shown to predict negative
health outcomes in several clinical and community-dwelling
populations [2, 11]. Following a standardised procedure [12],
we developed an FI with data collected in the HA-ID study.
The index consisted of 51 deﬁcits that were all (i) related to
health, (ii) positively associated with age, (iii) frequently but
not too often present in the population (>5%, <80%) and (iv)
no more than 30% of the outcomes values were missing.
Furthermore, the deﬁcits did not correlate too strongly with
each other (r< 0.7), and together, they covered different health
aspects. All deﬁcits were re-coded to a score between 0 (deﬁcit
absent) and 1 (deﬁcit present). An FI score was calculated by
the number of present deﬁcits divided by the total number of
measurements, resulting in a score ranging from zero (lowest
level of frailty) to one (highest level of frailty). A complete list
of the deﬁcits, used measurements and cut-off values has been
presented elsewhere [3]. Cholesterol, glucose and haemoglobin
were originally included in the FI. Therefore, per deﬁnition,
these measures are somewhat correlated with the FI. To elimin-
ate this correlation, the index was recomposed without the
item of interest for each biochemical measure.
Statistical analysis
First, to test for selection bias, participants for whom blood
samples were available were compared with non-participants
using Pearson χ2 tests (categorical variables) and t-tests (con-
tinuous variables). Second, regression analyses were performed
with the biochemical measures as dependent variables and the
FI as independent variable. Linearity between biochemical mea-
sures and frailty could not be assumed. Therefore, a curve esti-
mation procedure was used to ﬁnd the best ﬁt of the model for
each biochemical measure and if required a polynomial effect
was added to the model. The physiological measures were
incorporated into the models on a continuous scale, with an ex-
ception for IL-6, which was dichotomised at the detection limit
(19.5 pg/ml). Three different linear regression models were
created. The ﬁrst analysed the unadjusted association between
the biochemical measures and frailty (to aid interpretation,
multiplied by 100). Participant’s characteristics (gender, age,
level of ID and Down syndrome) were entered into a second
model. Dummy variables were composed for Down syn-
drome (the presence of Down syndrome or unknown status
versus no Down syndrome) and for the level of ID (moderate
or severe/profound versus borderline/mild). Furthermore,
potential confounders were entered per biochemical measure:
vitamin D was adjusted for vitamin D supplementation and
the period (summer/winter) of blood collection, calcium for
calcium supplementation, anaemia for iron supplementation,
glucose for glucose-lowering drugs and cholesterol/HDL/
triglycerides for lipid-lowering drugs. The third model incor-
porated all biochemical measures from the same functional
category and the baseline characteristics. The following
functional categories were deﬁned: inﬂammation (CRP and
IL-6), anaemia (haemoglobin), micronutrients (vitamin-D and
calcium), metabolic markers (glucose, triglycerides, cholesterol
and albumin) and renal functioning (creatinine and cystatine-c).
SPSS version 21.0 (SPSS, Inc., Chicago, IL, USA) was used
for statistical analyses. Results were considered statistically
signiﬁcant if the P value was <0.05.
Results
Baseline characteristics
For 757 out of 1,050 of the HA-ID participants, at least one
biochemical measure was available; 293 participants were
excluded, because they had no information on biochemical
measures. The included participants did not show signiﬁcant
differences with regard to gender, level of ID, age and the
presence of Down syndrome (Table 1). Those who were
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excluded showed slightly lower mean FI scores and were
more often living in the community compared with the
included participants.
Association between frailty and available
biochemical measures
Unadjusted and adjusted for age, gender, level of ID and
Down syndrome, higher FI scores were associated with higher
levels of IL-6, CRP and cystatin-C and with lower levels of
haemoglobin, cholesterol, glucose and albumin (Table 2;
Models 1 and 2), although the associations between choles-
terol and IL-6 weakened after adjusting for other biochemical
measures from the same system (Table 2; Model 3). Calcium
and creatinine showed a non-linear association with the FI
score; either a high or a low calcium/creatinine level was
associated with higher FI scores.
Discussion
For the ﬁrst time, we showed associations between frailty and
biochemical measures in a large, nearly representative, popula-
tion of older people with ID (50 years and over) receiving
specialised support or care. Frailty was associated with inﬂam-
mation, anaemia, metabolic markers and renal functioning.
Chronic inﬂammation can result in organ damage, muscle
waste and chronic diseases, which all contribute to frailty [2].
The other way around, inﬂammation arises as a consequence
of chronic diseases such as atherosclerosis, Alzheimer de-
mentia and type 2 diabetes [13]. For years, IL-6 has been
called the cytokine for gerontologists [14], and IL-6, CRP
and other inﬂammatory markers have frequently been asso-
ciated with both ageing and frailty [15, 16]. In line, we found
that elevated levels of IL-6 and CRP were associated with
higher FI scores.
The consequences of low levels of haemoglobin (e.g.
fatigue, low muscle strength, cognitive decline) are frequently
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Baseline descriptive characteristics of the HA-ID study
Included Excluded All Statistics
Test P value
n 757 293 1,050
Age (mean (SD)) 61.7 (8.0) 61.6 (8.3) 61.6 (8.0) 0.43 0.93
Gender (%) 0.55 0.46
Male 394 145 539
Female 363 148 511
Level of ID (%) 4.86 0.30
Borderline 19 12 31
Mild 154 69 223
Moderate 373 133 506
Severe 128 44 172
Profound 70 21 91
Unknown 13 14 27
Down syndrome (%) 0.03 0.87
Yes 111 38 149
No 544 180 724
Unknown 202 75 177
FI score (mean (SD)) 0.28 (0.12) 0.26 (0.14) 0.27 (0.13) 2.10 0.036
Residential status 33.5 <0.001
Central setting 430 127 557
Community based 296 137 433
Ambulatory support 30 20 50
Unknown 1 9 10
Biochemical measures n mean (SD)/number of abnormal values (%)
CRP (mg/l) 723 6.84 (18.0)
IL-6 (%, >19.5 pg/ml) 622 63 (10)
Haemoglobin (mmol, Fe/l) 735 8.74 (0.83)
Vitamin D (nmol/l) 618 63.3 (33.4)
Calcium (mmol/l) 585 2.22 (0.12)
Glucose (mmol/l) 724 5.01 (2.6)
HDL (mmol/l) 724 1.25 (0.38)
Triglycerides (mmol/l) 724 1.43 (0.76)
Cholesterol (mmol/l) 723 5.29 (1.04)
Albumin (g/l) 724 42.2 (3.83)
Creatinine (µmol/l) 634 75.2 (19.9)
Cystatin-C (mg/l) 634 1.05 (0.26)
SD, standard deviation; ID, intellectual disability, the total number of included biochemical measurements depended on the availability and successfulness of the
laboratory measurements.
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observed in frail individuals [17], which could explain the as-
sociation we found. The scarce amount of literature on the
association between frailty and haemoglobin shows inconsist-
ent results [18].
In contrast to most results observed in the general popu-
lation [4, 6, 7], we were unable to ﬁnd an inverse association
between vitamin D and frailty. Even though we adjusted for
supplements prescribed by the physician, we were unable to
adjust for over-the-counter-drugs that may have included
vitamin D supplementation. This could have interfered with
our results.
Serum albumin is the most abundant blood protein in
human beings, and low levels are associated with malnutrition,
disease and inﬂammation. Therefore, alteration in serum
albumin can reﬂect complications in multiple systems. Not sur-
prisingly, frailty, related to failure in several organs and systems,
was found to have a strong inverse association with albumin in
the general population [4, 15]. In accordance with these studies,
we found that low albumin concentrations were associated with
higher FI scores. We found an association between low levels of
glucose and cholesterol and frailty, but this association disap-
peared if adjusted for albumin. Nevertheless, these results
suggest that a poor nutritional status is associated with higher
frailty.
Last, we found a rather strong association between creatin-
ine, cystatin-C and frailty. In the general population, a higher
prevalence and incidence of frailty was observed for participants
with lower levels of kidney functioning measured with
cystatin-C [19]. The consequences of kidney failure could result
in a higher prevalence of frailty [20]. Additionally, cystatin-C has
frequently shown to predict cardiovascular outcomes [21].
Alternatively, cystatin-C may be associated with a chronic in-
ﬂammatory state in frail individuals [22].
These results provide an important basis for future research
into both the understanding of frailty in people with ID and
the possibility to the identiﬁcation of frail individuals. Special
focus should be given to inﬂammation. Ageing is characterised
by a low-grade chronic inﬂammatory status, termed ‘inﬂamma-
ging’. Inﬂammaging is associated with and predictive for
several chronic diseases and adverse health outcomes [23].
Although the exact aetiology needs to be further investigated,
we showed, in line with others, an association between inﬂam-
mation and frailty. Carmeli et al. [9] showed that overall, people
with unspeciﬁed ID (n= 15) have an increased inﬂammatory
state. These results imply that a chronic inﬂammatory state in
people with ID could partly explain the early onset of frailty.
We included only 12 biochemical measures, but many more are
known to be associated with frailty (e.g. TNF, oxidative stress).
Similarly, because frailty is characterised by abnormalities
across different systems, a combination of biochemical mea-
sures rather than a single biomarker is likely to be required to
measure frailty [24, 25].
Our study has several limitations. First and most important,
the cross-sectional design is not suited to study causal effects. It
is therefore unknown whether alterations in the studied bio-
chemical measures contributed to the incidence of frailty, or
that being frail affects physical processes leading to deviated bio-
chemical measures. Second, people of whom no blood sample
was available had slightly lower FI scores and were more often
living in the community, leading to an over-representation of
people living at central settings. Last, contrary to most studies,
we used an FI to measure frailty instead of the clinical frailty
phenotype, in which frailty is deﬁned as the presence of three
or more of the following characteristics: weight loss, exhaustion,
weakness, slow walking speed and low physical activity [26].
Even so, Hubbard et al. [16] showed that the associations
between biochemical markers and frailty are consistent across
the two frailty measures. In addition, the FI seems to be a more
suitable measure for people with ID (Schoufour et al., submit-
ted) and has shown predictive validity in this group [27, 28].
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. The unstandardised and standardised regression coefficient (β) with 95% CI, for the predictive value of biochemical
measures for frailty
System Biochemical measure n Model 1 Model 2 Model 3
B (95% CI) β B (95% CI) β B (95% CI) β
Inflammation IL-6 <19.5 pg/ml 594 4.73 (1.42 to 8.04) 0.11 3.57 (0.76 to 6.39) 0.09 2.50 (−0.37 to 5.38) 0.06
CRP 685 0.14 (0.09 to 0.20)* 0.20 0.09 (0.05 to 0.14)* 0.14 0.08 (0.03 to 0.12) 0.11
Anaemia Haemoglobin 691 −5.24 (−6.31 to −4.17)* −0.35 −3.66 (−4.69 to −2.63)* −0.24 NA NA
Micronutrients Vitamin D 589 0.04 (0.01 to 0.07) 0.11 0.002 (−0.03 to 0.03) 0.01 −0.001 (−0.04 to 0.03) −0.004
Calcium 559 −300 (−478.6 to −122.1) −2.94 −132.3 (−284.3 to −19.67) −1.30 −137.3 (−289.1 to 14.4) −1.35
Calcium2 559 66.9 (27.0 to 106.7) 2.93 30.85 (−3.06 to 64.75) 1.35 31.15 (−2.71 to 65.0) 1.37
Metabolic markers Glucose 673 −0.42 (−0.78 to −0.06) −0.09 −0.36 (−0.66 to −0.05) −0.08 −0.21 (−0.50 to 0.08) −0.04
HDL 673 −1.20 (−3.79 to 1.39) −0.04 −0.90 (−3.10 to 1.31) −0.03 −0.24 (−2.78 to 2.32) −0.01
Triglycerides 673 −0.42 (−1.67 to 0.83) −0.03 0.06 (−0.99 to 1.10) 0.00 0.52 (−0.77 to 1.81) 0.03
Cholesterol 672 −2.02 (−2.94 to −1.10)* −0.17 −1.37 (−2.20 to −0.53) −0.11 −0.30 (−1.25 to 0.66) −0.25
Albumin 686 −1.21 (−1.44 to −0.98)* −0.37 −0.79 (−1.01 to −0.57)* −0.24 0.73 (−0.97 to −0.49)* 0.12
Renal functioning Creatinine 606 −0.37 (0.56 to −0.18)* −0.58 −0.30 (0.47 to −0.14)* −0.48 −0.37 (−0.52 to −0.21)* −0.57
Creatinine2 606 0.002 (0.001 to 0.003)* 0.54 0.001 (0.001 to 0.002) 0.45 0.001 (0.00 to 0.002) 0.12
Cystatin-C 606 12.6 (8.87 to 16.3)* 0.26 9.53 (5.85 to 13.22)* 0.20 17.6 (13.03 to 22.3)* 0.37
Model 1: unadjusted; Model 2: adjusted for gender, age, level of ID, Down syndrome and drug/supplement use; Model 3: adjusted for gender, age, level of ID, Down
syndrome and all system measures mentioned in the table; Bold text = P value <0.005.
*P values <0.001.
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In conclusion, we showed associations between frailty and
biochemical measures in people with ID. In line with the litera-
ture, we found associations between frailty and inﬂammation,
metabolic markers, haemoglobin and kidney functioning. We
suggest that future research focuses on the possible effect of
inﬂammaging on frailty in people with ID, using prospective
study designs. In addition, the effect of a poor nutritional status
and frailty needs further examination. This knowledge may not
only lead to interventions but also to a possible biomarkers that
may be used to screen for frailty in a population with difﬁculties
using general frailty screening measures (e.g. self-report ques-
tionnaires or physical performance tests). Previously, we showed
that the consequences of frailty in people with ID are severe:
high frailty scores are related to mortality, increased disability,
decreased mobility, diseases and higher care intensity. It is very
important to prevent frailty as early as possible. Studies from
the general population show that frailty is difﬁcult to treat if
scores are already high. Biochemical measures can help to early
identify frail individuals and provide information on possible
pathways involved in the early onset of frailty in people with ID.
Key points
• People with ID show signs of early frailty.
• Frailty is associated with inﬂammation.
• Frailty is associated with nutritional status.
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Abstract
Background: UK National Dementia Strategies prioritise fair access to dementia treatments for the whole population. We
investigated for the ﬁrst time inequalities in NHS national dementia prescribing and how they have varied between UK coun-
tries and over time.
Method: we investigated the association between Townsend deprivation score and anti-dementia drug prescribing in 77,045
dementia patients from UK primary care records from 2002 to 2013.
Results: we included 77,045 patients with recorded dementia diagnosis or anti-dementia drug prescription. Least deprived
patients were 25% more likely to be initiated on anti-dementia drugs than the most deprived (adjusted incidence rate ratio 1.25,
95% conﬁdence interval 1.19–1.31). This was driven by data from English practices where prescribing rates were consistently
lower in more deprived patients compared with Scotland, Northern Ireland and Wales, where prescribing was not related to de-
privation quintile. Compared with English practices, anti-dementia medication was prescribed more often in Northern Irish
(1.81, 1.41–2.34) and less in Welsh practices (0.68, 0.55–0.82), with a trend towards more prescribing in Scottish practices
(1.14, 0.98–1.32). Drug initiation rates were also higher in younger people and men.
Conclusion: four years after the English National Dementia Strategy, there is no evidence that the Strategy’s key objective of
reducing treatment inequalities is being achieved. Higher overall anti-dementia drug prescribing in Scottish and Northern Irish
practices, and differing clinical guidelines in Scotland from other UK countries might explain greater equality in prescribing in
these countries. Strategies to offer treatment to more deprived people with dementia in England are needed.
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